PCSK9

Proprotein convertase subtilisin/kexin type 9 · Q8NBP7 · PCSK9 on Sugi Atlas →

23,464 patent compounds predicted against PCSK9, 14,869 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Nilotinib (SCHEMBL2098626)	0.86	9/20
SCHEMBL1954660	0.86	9/20
Eptifibatide (SCHEMBL43237)	0.57	9/20
Eptifibatide (SCHEMBL1649793)	0.57	9/20
Nilotinib (SCHEMBL7901)	1.00	8/20
Nilotinib (SCHEMBL434496)	0.99	8/20
Nilotinib (SCHEMBL1459790)	0.99	8/20
Nilotinib (SCHEMBL1565706)	0.99	8/20
Nilotinib (SCHEMBL1984397)	0.99	8/20
Nilotinib (SCHEMBL235245)	0.97	8/20
Nilotinib (SCHEMBL1460791)	0.97	8/20
Nilotinib (SCHEMBL2223849)	0.97	8/20
Nilotinib (SCHEMBL2102072)	0.96	8/20
Nilotinib (SCHEMBL1124112)	0.95	8/20
Nilotinib (SCHEMBL2099740)	0.95	8/20
Eptifibatide (SCHEMBL15781)	0.56	8/20
Eptifibatide (SCHEMBL571287)	0.56	8/20
Eptifibatide (SCHEMBL2686801)	0.49	7/20
Eptifibatide (SCHEMBL1890434)	0.56	6/20
SCHEMBL683921	0.51	6/20

Clinical trials — most relevant to PCSK9 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effect of Evolocumab on Vascular Function	PHASE4	COMPLETED
Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI	PHASE4	ACTIVE_NOT_RECRUITING
PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke	PHASE4	NOT_YET_RECRUITING
Lipid Management in Renal Transplant Recipients Using Evolocumab.	PHASE4	COMPLETED
Effect of Evolocumab on Chronic Total Occlusions (EVOLO-CTO)	PHASE4	UNKNOWN
Impact of Early PCSK9 Inhibitor on Heart After Acute Myocardium Infarction	PHASE4	RECRUITING
Inclisiran Effectiveness in China: a Pragmatic Randomized Trial	PHASE4	ACTIVE_NOT_RECRUITING
PCSK 9 Inhibition as Secondary Prevention in Renal Transplant Patients	PHASE3	COMPLETED
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))	PHASE3	COMPLETED
Application of PCSK9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia	PHASE3	UNKNOWN
Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)	PHASE3	COMPLETED
PCSK9 Inhibitors in Acute Ischemic Stroke Patients Undergoing Endovascular Therapy	PHASE2/PHASE3	NOT_YET_RECRUITING
Effect of Alirocumab on Postprandial Hyperlipemia in Patients With Type 2 Diabetes	PHASE3	COMPLETED
Adult Subjects With Elevated Low-Density Lipoprotein-Cholesterol to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects	PHASE1	COMPLETED
A Study to Investigate the Effect of AZD0780 on Metformin Pharmacokinetics in Healthy Adult Volunteers Aged 18 to 55 Years	PHASE1	COMPLETED
Pharmacodynamic Biomarkers to Support Biosimilar Development: PCSK9 Inhibitors	PHASE1	COMPLETED
The Danish Familial Hypercholesterolemia Organized Coronary Screening Trial	nan	ACTIVE_NOT_RECRUITING
Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD) a Registry of High Cardiovascular Risk Subjects in the United States	nan	COMPLETED
Assessment of Lipoprotein(a) and Endogenous Fibrinolysis in Atherosclerotic Cardiovascular Disease/Aortic Valve Disease	nan	RECRUITING
Sex Hormones and Blood PCSK9 Levels	nan	COMPLETED
Markers of Cardiovascular Risk in Patients With Premature Coronary Artery Disease and Treatment	nan	UNKNOWN
The Role of Proprotein-convertase-subtilisin/Kexin-type 9 in Kidney Damage in Nephrotic Syndrom	nan	RECRUITING
Kinetic Study of Lp(a) and PCSK9 in Humans	nan	COMPLETED
Randomized Controlled Trial of Alert-Based Computerized Decision Support for Optimizing Low-Density Lipoprotein Management	nan	ACTIVE_NOT_RECRUITING
Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population	nan	NOT_YET_RECRUITING
Subclinical Atherosclerosis in Patients With Familial Hypercholesterolemia Treated With Evolocumab®	nan	UNKNOWN
PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in Acute Coronary Syndromes (REPRESS)	nan	NOT_YET_RECRUITING
Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD	nan	ACTIVE_NOT_RECRUITING
Study to Evaluate Changes in Cognitive Function in Patients Treated With PCSK9 Inhibitors	nan	COMPLETED
Nudges for Statin Prescribing in Primary Care	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PCSK9 binder may also engage these)

Protein	Name	Similarity
A8T658	—	1.000	A8T658 →
A8T688	—	1.000	A8T688 →
A8T682	—	1.000	A8T682 →
A8T695	—	1.000	A8T695 →
A8T666	—	1.000	A8T666 →
A8T662	—	1.000	A8T662 →
A8T650	—	1.000	A8T650 →
A8T655	—	1.000	A8T655 →
A8T644	—	1.000	A8T644 →
A8T677	—	1.000	A8T677 →
A8T6A6	—	1.000	A8T6A6 →
A8T672	—	1.000	A8T672 →
A8T6A1	—	0.999	A8T6A1 →
Q80W65	—	0.998	Q80W65 →
P59996	—	0.998	P59996 →
PCSK7	Proprotein convertase subtilisin/kexin type 7	0.983	landscape →
Q61139	—	0.982	Q61139 →
Q8BNJ2	—	0.981	Q8BNJ2 →
Q9TT93	—	0.978	Q9TT93 →
Q62849	—	0.977	Q62849 →
P17491	—	0.976	P17491 →
Q9R0S3	—	0.976	Q9R0S3 →
P29121	—	0.975	P29121 →
Q8WXS8	—	0.975	Q8WXS8 →
Q04999	—	0.975	Q04999 →
P42917	—	0.974	P42917 →
O95450	—	0.974	O95450 →
ADAMTS7	A disintegrin and metalloproteinase with thrombospondin motifs 7	0.974	landscape →
A0A286YEC0	—	0.974	A0A286YEC0 →
Q0V8J4	—	0.974	Q0V8J4 →